BRAF and brain neoplasm: In addition to being potent against KIAA1549:BRAF, tovorafenib is brain-penetrant, and as such, it is being evaluated in PLGA, a brain tumor that is frequently driven by the KIAA1549:BRAF fusion (37, 41).